Testing a new drug for advanced solid tumors with certain gene changes
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced cancer that has spread or cannot be removed by surgery, and it must be measurable.
- Your tumor must have a RAS gene change (KRAS, NRAS, or HRAS), an EGFR gene change, or high levels of HER2 protein.
- You should be able to take pills by mouth and be in fairly good health (able to do most daily activities).
- You cannot have active cancer in the brain, uncontrolled high blood pressure, certain heart problems, or active hepatitis B or C.
- You cannot have a history of inflammatory bowel disease or conditions that affect how your body absorbs nutrients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.